News
- November 8, 2023
- Asahi Kasei Pharma and SBI Biotech announce start of Phase 1 study to evaluate AK1910 as a potential treatment for autoimmune diseases
- September 29, 2023
- Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba™ Capsule 40 mg as additional formulation in Japan
- September 5, 2023
- Notice of Issuance of a Provisional Disposition Order on Patent Infringement against a Generic of “Teribone™ Injection”
- August 30, 2023
- Announcement of listing on the NHI drug price standard and marketing of Empaveli® Subcutaneous Injection 1080 mg in Japan
- June 30, 2023
- Result of NEDO Smart Cell Project leads to commercial product Contributing to dyslipidemia testing through supply of material for in vitro diagnostic assays
- May 24, 2023
- Announcement of listing on the NHI drug price standard and marketing of Doptelet® Tablet 20 mg in Japan
- March 15, 2023
- Announcement of listing on the NHI drug price standard and marketing of Cresemba™ Capsule 100 mg and Cresemba™ Intravenous Infusion 200 mg in Japan
- March 13, 2023
- Asahi Kasei Pharma announces the start of a Phase 1 study of next-generation, long-acting GLP-2 analog peptide apraglutide in Japan
- December 23, 2022
- Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba™ Capsule 100 mg and Cresemba™ Intravenous Infusion 200 mg in Japan
- December 9, 2022
- Announcement of listing on the NHI drug price standard and marketing of bag product of Reclast® for i.v. infusion 5 mg
- September 15, 2022
- Asahi Kasei Pharma and Swedish Orphan Biovitrum Japan conclude exclusive distribution agreement for pegcetacoplan, a complement C3 inhibitor for paroxysmal nocturnal hemoglobinuria, and avatrombopag, an agent for improving thrombocytopenia associated with chronic liver disease
- August 10, 2022
- Approval of additional bag formulation of Reclast® for i.v. infusion 5 mg
- August 5, 2022
- Asahi Kasei Pharma to solicit proposals for drug discovery research
- June 14, 2022
- Alchemedicine and Asahi Kasei Pharma Enter into Exclusive License Agreement for Selective Endothelin A Receptor Antagonist
- April 28, 2022
- Asahi Kasei Pharma filed for provisional injunctions against infringement of patent rights of “TeriboneTM Injection”
- March 31, 2022
- Asahi Kasei Pharma signs exclusive license agreement with VectivBio to develop and commercialize next-generation GLP-2 analog peptide apraglutide in Japan
- March 28, 2022
- Start of Japan-US international phase 1 study of ART-123 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN)
- October 7, 2021
- Asahi Kasei Pharma to solicit proposals for drug discovery research
- September 30, 2021
- Asahi Kasei Pharma files application for approval to manufacture and sell AK1820 (isavuconazonium sulfate) in Japan
- September 30, 2021
- Asahi Kasei Pharma obtains exclusive option for AGN1 LOEP Hip Kit
Page Top
Copyright © Asahi Kasei Pharma Corporation. All Rights Reserved.